Page 61 - RPIA_26-3

HYPERSENSITIVITY TO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS:
FROM PATHOGENESIS TO CLINICAL PRACTICE / ARTIGO DE REVISÃO

21. Kis B, Snipes JA, Busija DW. Acetaminophen and the cyclooxy- 35. Yocum D, Fleischmann R, Dalgin P, Caldwell J, Hall D RP. Safety
genase -3 puzzle: sorting out facts, fictions, and uncertainties. J and efficacy of meloxicam in the treatment of osteoarthritis: a
Pharmacol Exp Ther 2005;315:1 -7. 12 -week, double -blind, multiple -dose, placebo -controlled trial.
22. Blanca -Lopez N, Perez -Alzate D, Andreu I, Dona I, Agundez JA, The Meloxicam Osteoarthritis Investigators. Arch Intern Med
Garcia -Martin E, et al. Immediate hypersensitivity reactions to 2000;160:2947 -54.
ibuprofen and other arylpropionic acid derivatives. Allergy 36. Bavbek S, Dursun AB, Dursun E, Eryilmaz A, Misirligil Z. Safety
2016;71:1048 -56. of meloxicam in aspirinhypersensitive patients with asthma and/
23. Panara MR, Renda G, Sciulli MG, Santini G, Di Giamberardino M, or nasal polyps. A challenge -proven study. International Archives
Rotondo MT, et al. Dose -dependent inhibition of platelet cycloox- of Allergy and Immunology 2007;142:64 -9.
ygenase -1 and monocyte cyclooxygenase -2 by meloxicam in 37. Goksel O, Aydin O, Misirligil Z, Demirel YS, Bavbek S. Safety of
healthy subjects. J Pharmacol Exp Ther 1999;290:276 -80. meloxicam in patients with aspirin/non -steroidal anti -inflammatory
24. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new in- drug -induced urticaria and angioedema. Journal of Dermatology
hibitors, and lessons from the clinic. FASEB J 2004;18:790 -804. 2010;37:973 -9.
25. Sánchez -Borges M, Caballero -Fonseca F, Capriles -Hulett A, 38. Senna G, Bilo MB, Antonicelli L, Schiappoli M, Crivellaro MA,
González -Aveledo L. Hypersensitivity Reactions to Nonsteroidal Bonadonna P, et al. Tolerability of three selective cyclo -oxygenase -2
Anti -Inflammatory Drugs: An Update. Pharmaceuticals 2010;3:10 -8. inhibitors, meloxicam, celecoxib and rofecoxib in NSAIDsensitive
26. Mangodt EA, Van Gasse AL, Decuyper I, Uyttebroek A, Faber patients. Eur Ann Allergy Clin Immunol 2004;36:215 -8.
MA, Sabato V, et al. In vitro Diagnosis of Immediate Drug Hyper- 39. Malheiro D, Cadinha S, Rodrigues J, Castel -Branco MG. Hiper-
sensitivity: Should We Go with the Flow. Int Arch Allergy Immu- sensibilidade a AINEs: o papel dos inibidores da COX -2 como
nol 2015;168:3 -12. fármacos alternativos. Rev Port Imunoalergologia 2005;13:243 -50.
27. Nizankowska E, Bestyńska -Krypel A, Cmiel A, Szczeklik A. Oral 40. Dworzynski K, Ardern -Jones M, Nasser S. Guideline Development
and bronchial provocation tests with aspirin for diagnosis of Group; National Institute for Health and Care Excellence. Diag-
aspirin -induced asthma. Eur Respir J 2000;15:863 -9. nosis and management of drug allergy in adults, children and young
28. Morais -Almeida M, Marinho S, Gaspar A. Montelukast in 2 ato pic people: summary of NICE guidance. BMJ 2014;349:g4852.
patients with intolerance to nonsteroidal anti -inflammatory drugs 41. Morales DR, Lipworth BJ, Guthrie B, Jackson C, Donnan PT,
and paracetamol: 5 -year follow -up. J Investig Allergol Clin Immu- Santiago VH. Safety risks for patients with aspirin -exacerbated
nol 2007;17:278 -9. respiratory disease after acute exposure to selective nonsteroidal
29. Settipane RA, Schrank PJ, Simon RA, Mathison DA, Christiansen anti -inflammatory drugs and COX -2 inhibitors: Meta -analysis of
SC, Stevenson DD. Prevalence of cross -sensitivity with acetami- controlled clinical trials. J Allergy Clin Immunol 2014;134:40 -5.
nophen in aspirin -sensitive asthmatic subjects. J Allergy Clin Im- 42. Couto M, López -Salgueiro R, Gaspar Â. Anaphylaxis to Etoricox-
munol 1995;96:480 -5. ib. J Investig Allergol Clin Immunol 2018;28:135 -6.
30. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, 43. Malskat WS, Knulst AC, Bruijnzeel -Koomen CA, Röckmann H.
Elton TS, et al. COX -3, a cyclooxygenase -1 variant inhibited by Tolerance to alternative cyclooxygenase -2 inhibitors in nonsteroi-
acetaminophen and other analgesic/antipyretic drugs: cloning, struc- dal anti -inflammatory drug hypersensitive patients. Clin Transl
ture, and expression. Proc Natl Acad Sci USA 2002;99:13926 -31. Allergy 2013;3:20.
31. Bavbek S, Celik G, Ozer F, Mungan D, Misirligil Z. Safety of se- 44. Weberschock TB, Muller SM, Boehncke S, Boehncke WH. Tole-
lective COX -2 inhibitors in aspirin/nonsteroidal anti -inflammatory rance to coxibs in patients with intolerance to non -steroidal
drug -intolerant patients: comparison of nimesulide, meloxicam, anti -inflammatory drugs (NSAIDs): a systematic structured review
and rofecoxib. J Asthma 2004;41:67 -75. of the literature. Arch Dermatol Res 2007;299:169 -75.
32. Celik GE, Erkekol FO, Aydin O, Demirel YS, Misirligil Z. Are drug 45. Asero R, Quaratino D. Cutaneous hypersensitivity to multiple
provocation tests still necessary to test the safety of COX -2 NSAIDs: never take tolerance to selective COX -2 inhibitors (COX-
inhibitors in patients with cross -reactive NSAID hypersensitivity? IBs) for granted! Eur Ann Allergy Clin Immunol 2013;45:3 -6.
Allergol Immunopathol (Madr) 2013;41:181 -8. 46. Dona I, Blanca -Lopez N, Jagemann LR, Torres MJ, Rondon C,
33. Kowalski ML, Makowska J. Use of nonsteroidal anti -inflammatory Campo P, et al. Response to a selective COX -2 inhibitor in patients
drugs in patients with aspirin hypersensitivity: safety of cyclo- with urticaria/angioedema induced by nonsteroidal anti-
-oxygenase -2 inhibitors. Treat Respir Med 2006;5:399 -406. -inflammatory drugs. Allergy 2011;66:1428 -33.
34. Faria E, Tomás MR, Carrapatoso I. Intolerância aos anti- 47. Morais -Almeida M, Marinho S, Rosa S, Gaspar A, Rosado -Pinto
-inflamatórios não esteróides: atitude diagnóstica e alternativa JE. Multiple drug intolerance including etoricoxib. Allergy
terapêutica. Via Pneumológica 1995;8:47 -57. 2006;61:144 -5.

219

REVIST A POR TUGUESA DE IMUNO ALERGOLOGIA